Angelini Pharma's R&D chief heads for the exit

News
Dr Rafal Kaminski.
Angelini Pharma

Dr Rafal Kaminski is due to depart Angelini Pharma at the end of this month.

Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.

The privately held company, which is in the throes of integrating US company Catalyst Pharma, acquired for $4.1 billion in July, confirmed Kaminski's departure today, noting that chief business officer Dr Preethi Sundaram will take over his responsibilities while it searches for a new CSO.

Angelini Pharma said that Kaminski has been "instrumental in reshaping the company's R&D organisation, attracting talented professionals and strengthening the expertise and capabilities of the teams." He is also credited with building up the company's pipeline of central nervous system (CNS) disorder therapies, particularly in epilepsy.

There is no word yet on Kaminski's plans after he departs Angelini Pharma, which is part of Angelini Industries. He has previously held roles at Molecure, Roche, UCB, and the National Institutes of Health (NIH) in the US.

"We respect Rafal's decision and thank him for his dedication, commitment and valued contribution," said Sergio Marullo di Condojanni, chief executive of Angelini Pharma.

"The foundations he has laid will continue to support our R&D capabilities as we pursue our ambition to become a leading global pharmaceutical company anchored in world-class innovation."

In the last five years, Angelini has executed a major push to add to its pipeline through external partnerships, in-licensing technologies and drug candidates across small molecules, biologics, and RNA-based therapies.

The flagship deal is the Catalyst takeover, which gave Angelini ownership of three FDA-approved products for neuromuscular diseases and epilepsy, which will immediately swell its revenues by around a third and provide a springboard into the US market.

Other recent deals include a genetic epilepsy-focused research collaboration with Quiver Bioscience, tapping into the latter's AI-powered discovery platform, as well as a $550 million deal to license rights to Sovargen's antisense oligonucleotide SVG105 for drug-resistant childhood epilepsy and a $570 million alliance with GRIN Therapeutics to develop radiprodil for rare genetic epilepsies.

"I am very proud of everything we have achieved together at Angelini Pharma," said Kaminski. "Thanks to the talent and commitment of the R&D organisation, we have advanced innovative pipeline projects for the benefit of people living with CNS disorders, and I am confident the team will continue on this path into the future."